Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal hyperproliferation and inflammation

BACKGROUND: Psoriasis is a chronic autoimmune skin disease characterized by hyperproliferation of keratinocytes. Wide treatment options used to treat psoriasis is associated with various adverse effects. To overcome this nanoformulation is prepared. Selenium is an essential trace element and plays major role in oxidation reduction system. Toxicity and stability limits the applications of selenium. Toxicity can be reduced and stabilized upon preparation into nanoparticles.

RESULTS: Selenium nanoparticles (SeNPs) exhibit potent apoptosis through the generation of reactive oxygen species (ROS) with cell cycle arrest. SeNPs topical gel application produced significant attenuation of psoriatic severity with the abrogation of acanthosis and splenomegaly. SeNPs reduced the phosphorylation and expressions of MAPKs, STAT3, GSK-3β, Akt along with PCNA, Ki67, and cyclin-D1.

CONCLUSION: SeNPs inhibit various inflammation and proliferation mediated pathways and could be an ideal candidate for psoriasis therapy.

MATERIALS AND METHODS: SeNPs were characterized and various techniques were used to determine apoptosis and other molecular mechanisms. In vivo studies were performed by inducing psoriasis with imiquimod (IMQ). SeNPs were administered via topical route.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:19

Enthalten in:

Journal of nanobiotechnology - 19(2021), 1 vom: 13. Apr., Seite 101

Sprache:

Englisch

Beteiligte Personen:

Gangadevi, Vinod [VerfasserIn]
Thatikonda, Sowjanya [VerfasserIn]
Pooladanda, Venkatesh [VerfasserIn]
Devabattula, Geetanjali [VerfasserIn]
Godugu, Chandraiah [VerfasserIn]

Links:

Volltext

Themen:

EC 2.7.11.1
Glycogen Synthase Kinase 3 beta
H6241UJ22B
Imiquimod
Inflammation
Journal Article
P1QW714R7M
Proliferation
Psoriasis
Reactive Oxygen Species
Reactive oxygen species
STAT3 Transcription Factor
STAT3 protein, human
Selenium
Selenium nanoparticles

Anmerkungen:

Date Completed 14.10.2021

Date Revised 14.10.2021

published: Electronic

Citation Status MEDLINE

doi:

10.1186/s12951-021-00842-3

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM324044046